Literature DB >> 17317051

Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers.

Olga Borges1, Gerrit Borchard, Adriano de Sousa, Hans E Junginger, Anabela Cordeiro-da-Silva.   

Abstract

CD69 is a very early cell activation antigen expressed on the surface of activated immune cells. It can appear within 1-2h of activation and exhibits maximal expression levels between 18 and 24h after stimulation. In this work, the expression profile of CD69 in mice splenocytes was evaluated following exposure to the biopolymers, chitosan or alginate and the immunostimulatory factors, CpG ODN 1826 or concanavalin A. We have shown that both polymers are able to upregulate expression of CD69 on B cells and CD4+ T-lymphocytes, with alginate as the least potent stimulus. Moreover, the expression of the CD69 molecule on CD8+ T-lymphocytes was observed only in splenocytes cultured with chitosan. However, activation of lymphocytes did not result in cell proliferation. On the other hand, CpG ODN proved to be a potent B cell stimulator, as evidenced by the upregulation of CD69, but had less effect on T-cells. These results, together with previous discoveries reported in scientific literature, may contribute to the clarification of the adjuvant effect, which has been attributed to chitosan and alginate formulations or to the biopolymers itself.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317051     DOI: 10.1016/j.ijpharm.2007.01.021

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

1.  Ability of the polysaccharide chitosan to inhibit proliferation of CD4+ lymphocytes from mucosal inductive sites, in vitro and in vivo.

Authors:  C Porporatto; M M Canali; I D Bianco; S G Correa
Journal:  Cell Prolif       Date:  2009-08-17       Impact factor: 6.831

Review 2.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

3.  Evaluation of clinical biomaterial surface effects on T lymphocyte activation.

Authors:  Analiz Rodriguez; James M Anderson
Journal:  J Biomed Mater Res A       Date:  2010-01       Impact factor: 4.396

4.  Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB.

Authors:  Zhang Songjiang; Wu Lixiang
Journal:  AAPS PharmSciTech       Date:  2009-07-16       Impact factor: 3.246

5.  Licorice infusion: Chemical profile and effects on the activation and the cell cycle progression of human lymphocytes.

Authors:  José Cheel; Gabriela Onofre; Doris Vokurkova; Lenka Tůmová; Jarmila Neugebauerová
Journal:  Pharmacogn Mag       Date:  2010-02-13       Impact factor: 1.085

6.  Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins.

Authors:  Marcin M Grzybowski; Bożena Dziadek; Justyna M Gatkowska; Katarzyna Dzitko; Henryka Długońska
Journal:  Parasitol Res       Date:  2015-09-04       Impact factor: 2.289

7.  Absence of immune responses with xenogeneic collagen and elastin.

Authors:  Alexandra Bayrak; Pauline Prüger; Ulrich A Stock; Martina Seifert
Journal:  Tissue Eng Part A       Date:  2013-04-15       Impact factor: 3.845

8.  Oral administration of SSC201, a medicinal herbal formula, suppresses atopic dermatitis-like skin lesions.

Authors:  Bo-Kyung Park; Yang-Chun Park; In Chul Jung; Seung-Hyung Kim; Jung-Eun Choi; Sunyoung Park; Jeong June Choi; Mirim Jin
Journal:  J Med Food       Date:  2014-01-29       Impact factor: 2.786

9.  Antiasthmatic effects of hesperidin, a potential Th2 cytokine antagonist, in a mouse model of allergic asthma.

Authors:  Seung-Hyung Kim; Bok-Kyu Kim; Young-Cheol Lee
Journal:  Mediators Inflamm       Date:  2011-05-04       Impact factor: 4.711

10.  Afzelin attenuates asthma phenotypes by downregulation of GATA3 in a murine model of asthma.

Authors:  Wenbo Zhou; Xiuhong Nie
Journal:  Mol Med Rep       Date:  2015-02-26       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.